NVO vs VTVT
NVO: A global healthcare leader specializing in innovative treatments for diabetes, obesity, and other serious chronic conditions. VTVT: vTv Therapeutics is a late-stage biopharma company developing novel, oral treatments for diabetes and chronic diseases, highlighted by its Phase 3 lead candidate for type 1 diabetes.
Side-by-side fundamentals
| Metric | NVO | VTVT | Edge |
|---|---|---|---|
| Price as of 2026-10-20 close | $39.35 | $27.85 | |
| Market cap | $174.9B | $110M | |
| Net margin FY2025, SEC XBRL | +33.1% | n/a | |
| Gross margin FY2025, SEC XBRL | +81.0% | n/a | |
| Operating margin FY2025, SEC XBRL | +41.3% | n/a | |
| ROE FY2025, SEC XBRL | +52.8% | -41.9% | NVO higher |
| ROA FY2025, SEC XBRL | +18.9% | -30.0% | NVO higher |
| Revenue CAGR (3y) SEC XBRL | +20.4% | n/a | |
| Dividend yield as of 2026-09-03 | +2.7% | n/a | |
| Dividend streak (yrs) SEC XBRL | n/a | 0 | |
| Beta as of 2026-09-03 | 0.82 | 1.03 | |
| 1-year return as of 2026-10-20 close | -29.4% | +35.1% | VTVT higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.